Tenax Therapeutics, Inc.
$1.82
-$0.01 (-0.55%)
$1.81Day Range$1.93
Key Statistics
Market Cap
$68.11M
Shares Outstanding
37.4M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Feb 1, 1995
Round Lot
100
Locale
US
Trading Data
Day Open
$1.88
Day High
$1.93
Day Low
$1.81
Volume
2.29M
VWAP
$1.87
Prev Close
$1.83
Transactions
--
Acc. Volume
--
About Tenax Therapeutics, Inc.
Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.
PHARMACEUTICAL PREPARATIONSSIC 283416 employees101 GLEN LENNOX DRIVE, CHAPEL HILL, NC, 27517919-855-2100IPO Feb 1, 1995US / STOCKSActiveWebsite
Identifiers
- CIK
- 0000034956
- Composite FIGI
- BBG000BJ6R36
- Share Class FIGI
- BBG001S78GM3
- Ticker Root
- TENX
- SIC Code
- 2834
About Tenax Therapeutics, Inc. (TENX) Stock
Tenax Therapeutics, Inc. (TENX) closed the 2026-09-16 session at $1.82, down 0.55% versus the previous close (-0.01). The stock opened at $1.88 and traded between $1.81 and $1.93 during that session. Session trading volume was 2.3M shares. The volume-weighted average price (VWAP) is $1.87.
Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.
Tenax Therapeutics, Inc. has a market capitalization of $68.1 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. TENX is listed on the XNAS exchange. The company employs approximately 16 people. Tenax Therapeutics, Inc. is headquartered in CHAPEL HILL, NC. The recorded listing date is 1995-02-01.
On this page you can find market TENX stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.